

Resource Summary Report

Generated by [RRID](#) on Sep 6, 2026

DoCI1 (S+L-)

RRID:CVCL_4164

Type: Cell Line

Proper Citation

RRID:CVCL_4164

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_4164

Proper Citation: RRID:CVCL_4164

Sex: Female

Defining Citation: [PMID:52940](#)

Comments: Breed/subspecies: Cocker Spaniel., Derived from sampling site: Kidney., Transformant: NCBI_TaxID; 11801; Moloney murine leukemia virus (MoMuLV).

Category: Transformed cell line

Name: DoCI1 (S+L-)

Synonyms: S+L- DoCI1

Cross References: CLO:CLO_0002804, CLDB:cl1085, ATCC:CCL-34.1, ECACC:90102523, Wikidata:Q54831343

ID: CVCL_4164

Record Creation Time: 20220427T215821+0000

Record Last Update: 20260905T175236+0000

Ratings and Alerts

No rating or validation information has been found for DoCI1 (S+L-).

No alerts have been found for DoCI1 (S+L-).

Data and Source Information

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Ying B, et al. (2026) An intranasal adenoviral-vectored vaccine protects against highly pathogenic avian influenza H5N1 in naive and antigen-experienced animals. *Cell reports. Medicine*, 7(2), 102582.

Yang H, et al. (2026) Dual roles of USP39 in stabilizing PB2 and orchestrating ribonucleoprotein assembly drive H5 influenza virus replication and pathogenicity. *Cell reports*, 45(3), 117002.

Andersen H, et al. (2025) Immunopathogenesis of lethal H5N1 avian influenza virus clade 2.3.4.4b infection in macaques. *Immunity*, 58(9), 2157.

Takizawa N, et al. (2025) Concentration-dependent formation of intersegment interactions in the viral inclusions of influenza A virus infected cells. *iScience*, 28(10), 113606.

Barre RS, et al. (2025) A human H5N1 influenza virus expressing bioluminescence for evaluating viral infection and identifying therapeutic interventions. *iScience*, 28(9), 113402.

Rawi R, et al. (2025) The N terminus of H3-influenza hemagglutinin as a site-of-vulnerability to neutralizing antibody. *Structure (London, England : 1993)*.